In addition, pathogenic bacteria from the intestinal microbiota can interactively regulate IL-17A production from immune or non-immune cells, which plays a major role in regulating gut mucosal immunity and pathogenesis of NAFLD, and thus accelerates the progression of NAFLD, a highly related complication of atherosclerosis (19–22). Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.